Biobot Surgical and BEBIG Medical have signed a memorandum of understanding (MOU) to collaborate on a robotic-guided high dose rate (HDR) brachytherapy solution to treat prostate cancer patients.

Biobot Surgical has developed the iSR’obot Mona Lisa 2.0 robotic-guided percutaneous surgical system.

The device helps physicians plan as well as position needles for robotic-assisted diagnostic and interventional prostate procedures.

Biobot Surgical CEO Sim Kok Hwee said: “The partnership enables our companies to bring robotic-assisted brachytherapy solutions to patients.”

HDR brachytherapy is a radiotherapy form that involves the insertion of a thin tube into a patient’s prostate gland. A radiation source is passed through the tube to destroy cancer cells.

The ultrasound-guided HDR brachytherapy procedure usually uses a template grid to insert the needle into the prostate gland of a patient.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

For HDR brachytherapy, iSR’obot Mona Lisa 2.0 automatically guides the insertion of the needle within 1.0mm accuracy of the targeted needle position.

The robotic needle guide enables angulated needle trajectory for an optimal treatment plan while avoiding critical anatomical structures.

The device has secured 510(k) clearance from the US Food and Drug Administration (FDA) and is anticipated to receive EU MDR approval next year.

Currently, the first-generation iSR’obot Mona Lisa is marketed in Australia, Asia and Europe.

In clinical studies, the solution showed a clinically significant prostate cancer detection rate 81% higher than cognitive fusion biopsies.

BEBIG Medical chairman and CEO George Chan said: “The future trend of medical device technology was moving toward digitalisation, automation and artificial intelligence. The joint partnership is a vivid display of these orientations to achieve clinical excellence.”